keyword
MENU ▼
Read by QxMD icon Read
search

Gynecologic malignancies

keyword
https://www.readbyqxmd.com/read/28454476/parp-inhibition-sensitizes-endometrial-cancer-cells-to-paclitaxel-induced-apoptosis
#1
Christine Dinkic, Friederike Jahn, Marek Zygmunt, Florian Schuetz, Joachim Rom, Christof Sohn, Herbert Fluhr
PARP inhibitors are used in the treatment of gynecological malignancies and it has been demonstrated in preclinical studies that PARP inhibition sensitizes cancer cells to cytotoxic agents. In the present study, PARP expression was detected in different endometrial cancer cell lines by western blot analysis, and PARP activity was measured using an enzymatic assay. In addition, the endometrial cancer cell lines were treated with paclitaxel or carboplatin in combination with the PARP inhibitor PJ34 prior to a cell viability assay and apoptotic nuclei measurement...
April 2017: Oncology Letters
https://www.readbyqxmd.com/read/28454285/stereotactic-radiosurgery-for-brain-metastasis-from-gynecological-malignancies
#2
Ekkehard Kasper, Franziska Ippen, Eric Wong, Eric Uhlmann, Scott Floyd, Anand Mahadevan
Brain metastases are relatively uncommon in gynecological malignancies, and there is limited available data on their management. The present study reports the outcomes of patients with brain metastasis from gynecological malignancies who were treated with stereotactic radiosurgery (SRS). Patients with brain metastasis from a gynecological primary site were treated with SRS using the Cyberknife™ frameless SRS system. Primary lesions were treated with a single fraction of 16-22 Gy. A total of 3 resection cavities were treated with 8 Gy 3 times, meaning a total of 24 Gy, and 1 recurrent lesion was re-irradiated with 5 Gy 5 times, meaning a total of 25 Gy...
March 2017: Oncology Letters
https://www.readbyqxmd.com/read/28448435/a-resident-s-perspective-of-ovarian-cancer
#3
Christopher G Smith
Identifying, understanding, and curing disease is a lifelong endeavor for any medical practitioner. Equally as important is to be cognizant of the impact a disease has on the individual suffering from it, as well as on their family. Ovarian cancer is the leading cause of death from gynecologic malignancies. Symptoms are vague, and the disease is generally at an advanced stage at diagnosis. Efforts have been made to develop methods to identify ovarian cancer at earlier stages, thus improving overall mortality...
April 27, 2017: Diagnostics
https://www.readbyqxmd.com/read/28444622/a-brief-review-of-the-management-of-platinum-resistant-platinum-refractory-ovarian-cancer
#4
REVIEW
Bryan Oronsky, Carolyn M Ray, Alexander I Spira, Jane B Trepel, Corey A Carter, Hope M Cottrill
Ovarian cancer, which ranks fifth in cancer deaths among women, is the most lethal gynecologic malignancy. Epithelial ovarian cancer (EOC) is the most common histologic type, with the 5-year survival for all stages estimated at 45.6%. This rate increases to more than 70% in the minority of patients who are diagnosed at an early stage, but declines to 35% in the vast majority of patients diagnosed at advanced stage. Recurrent EOC is incurable. Platinum sensitivity (or lack thereof) is a major determinant of prognosis...
June 2017: Medical Oncology
https://www.readbyqxmd.com/read/28443516/synergistic-effect-of-graphene-oxide-coated-nanotised-apigenin-with-paclitaxel-go-na-ptx-a-ros-dependent-mitochondrial-mediated-apoptosis-in-ovarian-cancer
#5
Manish Kumar Pal, Shyam Pyari Jaiswar, Ashish Dwivedi, Shruti Goyal, Vinay Nand Dwivedi, Anumesh Kumar Pathak, Vinod Kumar, Pushp Lata Sankhwar, Ratan Singh Ray
Ovarian cancer is most lethal among all gynecologic malignancies. Paclitaxel (PTX) is well used chemotherapeutic regimen for cancer control; however its undesired toxicity has been always a matter of concern for clinicians. Here we used the graphene oxide coated nanotised apigenin (GO-NA) as chemo sensitizing agent to enhance the efficacy of paclitaxel to overcome the limitations of chemotherapy. GO and GO-Apigenin was prepared by modified Hummers method and the nanoparticles were characterized by dynamic light scattering and transmission electron microscopy Human ovarian adenocarcinomas (SKOV-3) cells was treated by DMSO, Group I (Control)-McCoy's 5A Medium, Group II-Paclitaxel (5nM) alone, Group III- Nanotised Apigenin (GO-NA-10μM) Group IV- Paclitaxel (5nM) + GO-NA (10μM)...
April 24, 2017: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/28442932/granular-cell-tumor-in-breast-a-case-report
#6
Maria Castillo Lara, Antonia Martínez Herrera, Rafael Torrejón Cardoso, Daniel Maria Lubián López
Granular cell tumor (GCT) is a rare neoplasm of the soft tissues, and <1% of all GCTs are malignant. It usually appears in the tongue and sometimes may affect the female breast. Initially, GCT was considered to be a myogenic lesion affecting female breast (myoblastoma). Actually, it is assumed as a tumor originating from perineural or putative Schwann cells of peripheral nerves or their precursors that grows in the lobular breast tissue, due to the immunohistochemical features. Here, we review the importance of differentiating between this tumor and malignant breast carcinoma...
2017: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28440189/better-predictive-value-of-cancer-antigen125-ca125-as-biomarker-in-ovary-and-breast-tumors-and-its-correlation-with-the-histopathological-type-grade-of-the-disease
#7
Aarifa Nazmeen, Smarajit Maiti, Kusumita Mandal, Samir K Roy, Tamal Kanti Ghosh, Nirmalya K Sinha, Kamalika Mandal
BACKGROUND: Both ovarian/breast cancers are the most prevalent hormone-associated gynecological-cancers, where uncontrolled cellular proliferations/genetic-errors are noticed. The cancer-antigen125 (CA125), which we assessed presently is an important biomarker in the early detection/monitoring of this disease-pathogenesis. METHODS: Serum/tissue CA125 was measured by solid-phase-Enzyme-linked-immunosorbent-assay in women with ovarian/breast tumors of different types (epithelial/non-epithelial; benign/borderline/malignant)/stages...
April 24, 2017: Medicinal Chemistry
https://www.readbyqxmd.com/read/28439256/the-role-of-endocrine-g-protein-coupled-receptors-in-ovarian-cancer-progression
#8
REVIEW
Qingyu Zhang, Nadine Ellen Madden, Alice Sze Tsai Wong, Billy Kwok Chong Chow, Leo Tsz On Lee
Ovarian cancer is the seventh most common cancer in women and the most lethal gynecological cancer, causing over 151,000 deaths worldwide each year. Dysregulated production of endocrine hormones, known to have pluripotent effects on cell function through the activation of receptor signaling pathways, is believed to be a high-risk factor for ovarian cancer. An increasing body of evidence suggests that endocrine G protein-coupled receptors (GPCRs) are involved in the progression and metastasis of ovarian neoplasms...
2017: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/28438473/bevacizumab-and-paclitaxel-carboplatin-chemotherapy-and-secondary-cytoreduction-in-recurrent-platinum-sensitive-ovarian-cancer-nrg-oncology-gynecologic-oncology-group-study-gog-0213-a-multicentre-open-label-randomised-phase-3-trial
#9
Robert L Coleman, Mark F Brady, Thomas J Herzog, Paul Sabbatini, Deborah K Armstrong, Joan L Walker, Byoung-Gie Kim, Keiichi Fujiwara, Krishnansu S Tewari, David M O'Malley, Susan A Davidson, Stephen C Rubin, Paul DiSilvestro, Karen Basen-Engquist, Helen Huang, John K Chan, Nick M Spirtos, Raheela Ashfaq, Robert S Mannel
BACKGROUND: Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed to explore the roles of secondary surgical cytoreduction and bevacizumab in this population, and report the results of the bevacizumab component here. METHODS: The multicentre, open-label, randomised phase 3 GOG-0213 trial was done in 67 predominantly academic centres in the USA (65 centres), Japan (one centre), and South Korea (one centre)...
April 21, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28436480/dihydromyricetin-induces-apoptosis-and-reverses-drug-resistance-in-ovarian-cancer-cells-by-p53-mediated-downregulation-of-survivin
#10
Yingqi Xu, Shengpeng Wang, Hon Fai Chan, Huaiwu Lu, Zhongqiu Lin, Chengwei He, Meiwan Chen
Ovarian cancer is one of the leading causes of death in gynecological malignancies, and the resistance to chemotherapeutic agents remains a major challenge to successful ovarian cancer chemotherapy. Dihydromyricetin (DHM), a natural flavonoid derived from Ampeopsis Grossdentata, has been widely applied in food industry and medicine for a long time. However, little is known about the effects of DHM on ovarian cancer and the underlying mechanisms. In this study, we demonstrated that DHM could effectively inhibit the proliferation of ovarian cancer cells and induce cell apoptosis...
April 24, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28434105/far-infrared-ray-for-treating-chronic-lower-extremity-lymphedema-with-dermatolymphangioadenitis-a-postoperative-complication-of-gynecological-tumor-resection
#11
Ke Li, Heng Xu, Ning Fei Liu, Parviz Sadigh, Verity Evans, Yi Xin Zhang
PURPOSE: Lower extremity lymphedema is regarded as a relatively common postoperative complication and is often accompanied with dermatolymphangioadenitis (DLA). This study combines clinical assessment and laboratory investigation to explore therapeutic effects of far-infrared radiation (FIR) therapy for chronic lower extremity lymphedema accompanied with DLA, occurring after gynecological tumor resection. METHODS: Patients who met inclusion and exclusion criteria would be enrolled...
April 22, 2017: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/28432169/primary-malignant-melanoma-of-the-cervix-a-rare-disease
#12
Ivo Julião, Sonia Dias Carvalho, Vanda Patricio, Ana Raimundo
Malignant melanoma (MM) arising primarily in the cervix is exceedingly rare and has a poor prognosis. We report the case of a primary MM of the cervix in a 64-year-old woman with vaginal bleeding. She presented with a cervical amelanotic lesion which on biopsy rendered the diagnosis of MM. The patient was staged as International Federation of Gynecology and Obstetrics IIB and underwent Wertheim-Meigshysterectomy followed by brachytherapy. One year later, she was diagnosed with a large pelvic relapse for which surgery was performed...
April 21, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28428125/ovarian-metastasis-of-a-malignant-melanoma-a-case-report
#13
A Mendel, J J Terzibachian, F Aubin, L Malicenco, R Ramanah, D Riethmuller
Malignant melanoma represents 3% of cancers at the woman. The metastatic gynecological localization are rare and ovary is an exceptional site. Prognosis of metastatic ovary malignant melanoma is pejorative (5% 5 years survival). We report a case observed in a 65-year-old patient, who developed 2 melanomas of the left leg and presented a right ovarian tumor during a supervision tomodensitometric 7 years after diagnostic initial. The immunohistochemical assays after annexectomy confirmed the diagnostic of ovarian metastasis...
April 17, 2017: J Gynecol Obstet Hum Reprod
https://www.readbyqxmd.com/read/28422385/genital-bleeding-hemostasis-in-gynecologic-neoplasm-with-balloon-tamponade-new-treatment-option
#14
Noriko Karakida, Shintaro Yanazume, Marie Mori, Natsuko Uchida, Akio Tokudome, Hiroaki Kobayashi
Genital bleeding is the most common and serious complication in gynecologic malignancy. Different techniques are available for the control of severe bleeding, but standard treatment strategies have not been determined. Herein we report on the successful use of the balloon technique in two cases of genital bleeding in uterine neoplasm. The first case was of advanced cervical cancer with massive genital bleeding during radiotherapy. A metreurynter (mini-metro) was inserted into the vagina and hemostasis was indirectly achieved in the vaginal hematoma...
April 19, 2017: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/28412839/awareness-and-knowledge-of-ovarian-cancer-symptoms-and-risk-factors-a-survey-of-jordanian-women
#15
Mazen Freij, Mohammad Al Qadire, Maysa Khadra, Mohammed ALBashtawy, Wael Tuqan, Mohammad Al Faqih, Ayoub Innabi, Abdul-Monim Batiha, Fadwa Alhalaiqa, Aida Abd El-Razek
Ovarian cancer accounts for 3% of all female cancers and has a high mortality rate among gynecological malignancies. Early diagnosis carries a high survival rate of 93%. So, this study was carried out to assess the knowledge and awareness of Jordanian women about ovarian cancer symptoms and risk factors. A cross-sectional survey design was used; 896 women completed the survey. The mean of total symptoms recognized was low at level of 3.2 ( SD = 2.7) out of 10. The three highest known symptoms among women were as follows: extreme fatigue (43...
April 1, 2017: Clinical Nursing Research
https://www.readbyqxmd.com/read/28412364/the-cytoplasmic-translocation-of-cx32-mediates-cisplatin-resistance-in-ovarian-cancer-cells
#16
Weili Wu, Lixia Fan, Zeqing Bao, Yu Zhang, Yuexia Peng, Min Shao, Yuke Xiang, Xiaomin Zhang, Qin Wang, Liang Tao
Ovarian cancer is the most lethal gynecologic malignancy, and cisplatin is one of the first-line chemotherapeutic agents. However, acquired cisplatin resistance prevents the successful treatment of patients with ovarian cancer. Gap junction (GJ) and connexin (Cx) are closely related to tumor formation, but the relationship between cisplatin resistance and GJ or Cx are undetermined. In this study, we established the cisplatin-resistant human ovarian cancer cell line A2780-CDDP. Here we showed that cisplatin resistance was correlated to the loss of GJ and the upregulation of Cx32 expression...
April 12, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28411145/current-and-future-role-of-genetic-screening-in-gynecologic-malignancies
#17
REVIEW
Kari L Ring, Christine Garcia, Martha H Thomas, Susan C Modesitt
The world of hereditary cancers has seen an exponential growth in recent years. While Hereditary Breast and Ovarian Cancer and Lynch syndrome account for the majority of mutations encountered by gynecologists, newly identified deleterious genetic mutations continue to be unearthed with their associated risks of malignancies. However, these advances in genetic cancer predispositions then force practitioners and their patients to confront the uncertainties of these less commonly identified mutations and the fact that there is limited evidence to guide them in expected cancer risk and appropriate risk reduction strategies...
April 11, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28410756/perioperative-sexual-interest-in-women-with-suspected-gynecologic-malignancies
#18
C Emi Bretschneider, Jeannette T Bensen, Elizabeth J Geller, Paola A Gehrig, Jennifer M Wu, Kemi M Doll
OBJECTIVES: For women with gynecologic cancer, the impact of surgery on sexual interest and desire in the immediate and later postoperative period is not well characterized. The objective of this study was to report the perioperative trends of changing sexual interest and desire in a cohort of women undergoing surgery for suspected gynecologic malignancies. METHODS: This is an ancillary analysis of a cohort study analyzing health-related outcomes in women who underwent primary surgical management of a suspected gynecologic malignancy between 10/2013 and 10/2014...
April 12, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28408840/clinical-course-and-outcome-of-patients-with-high-level-microsatellite-instability-cancers-in-a-real-life-setting-a-retrospective-analysis
#19
Naama Halpern, Yael Goldberg, Luna Kadouri, Morasha Duvdevani, Tamar Hamburger, Tamar Peretz, Ayala Hubert
BACKGROUND: The prognostic and predictive significance of the high-level microsatellite instability (MSI-H) phenotype in various malignancies is unclear. We describe the characteristics, clinical course, and outcomes of patients with MSI-H malignancies treated in a real-life hospital setting. PATIENTS AND METHODS: A retrospective analysis of MSI-H cancer patient files was conducted. We analyzed the genetic data, clinical characteristics, and oncological treatments, including chemotherapy and surgical interventions...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28408839/dnmt1-regulates-human-endometrial-carcinoma-cell-proliferation
#20
Xinjing Wang, Bilan Li
Endometrial carcinoma (EC) is the most common gynecologic malignancy, but the molecular events involved in the development and progression of EC remain unclear. This study aimed to investigate the role of DNA methyltransferase 1 (DNMT1), a member of DNA methyltransferases, in EC. AN3CA cells were transfected with DNMT1 siRNA. The proliferation, cell cycle, and apoptosis of AN3CA cells were evaluated by Cell Counting Kit-8 (CCK-8) assay and flow cytometry. The expression of related genes was detected by polymerase chain reaction and Western blot analysis...
2017: OncoTargets and Therapy
keyword
keyword
87373
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"